Artelo Biosciences Executes Reverse Split Amid Nasdaq Compliance Battle

SOLANA BEACH, CA – March 06, 2026 – Artelo Biosciences, a clinical-stage pharmaceutical company, announced today it will proceed with a 3-for-1 reverse stock split, a corporate maneuver aimed at bolstering its flagging share price. The split, approved by the Board of Directors on February 27, will take effect at the market open on March 10, 2026. While the company states the goal is to “improve its marketability and liquidity,” the move comes as Artelo navigates a perilous period of scrutiny from the Nasdaq stock exchange, raising critical questions about its future.

Under the terms of the reverse split, every three shares of Artelo's common stock will be consolidated into a single share. The company has confirmed that shareholders’ proportional ownership will remain unchanged, and any fractional shares will be rounded up to one whole share. Immediately following the action, the number of outstanding shares will shrink from over two million to approximately 708,258.

For investors, such a move is often a double-edged sword. On one hand, it is a standard tool for companies struggling with a low stock price. On the other, it is frequently viewed as a cosmetic fix that fails to address the fundamental issues that led to the price decline in the first place.

A Battle for Nasdaq Compliance

The timing of the reverse split is no coincidence. Artelo Biosciences has been under significant pressure from Nasdaq to meet its listing requirements. The company has been grappling with multiple compliance deficiencies, making the stock consolidation a critical, if not desperate, measure to remain on the exchange.

Most notably, in November 2025, Artelo received a delisting determination for failing to meet Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The company appealed the decision, allowing its stock to continue trading, but the underlying financial deficiency remained unresolved. This equity shortfall highlights the company's struggle to maintain a financial position robust enough for a public listing.

Adding to its regulatory woes, Artelo also faced a potential delisting for failing to hold its annual shareholder meeting on time, a procedural violation it rectified in late January 2026. However, the most pressing, albeit unstated, issue addressed by the reverse split is likely the exchange's minimum bid price requirement. Nasdaq rules mandate a stock maintain a closing bid price of at least $1.00. While Artelo's stock closed at $1.21 on March 4, it has flirted dangerously with the one-dollar threshold after having “cratered to penny-stock territory,” according to market observers. A reverse split is the most direct way to artificially inflate the share price and steer clear of a bid-price deficiency notice.

More Than Just a Numbers Game

For a company like Artelo, whose stock had fallen 94% from its 52-week high by late January, the reverse split is an attempt to reset market perception. A higher share price can make the stock more attractive to institutional investors and funds, many of which have internal policies that prohibit them from holding stocks trading below a certain price, often referred to as “penny stocks.”

The company's marketability has been hampered by extremely low trading volume, a sign of waning investor interest. On January 30, for instance, a mere 4,253 shares changed hands, leaving the company with a market capitalization of just $3.4 million—making it one of the smallest biotechs on the Nasdaq. By engineering a higher price, Artelo hopes to improve liquidity and draw in new, more stable investment.

However, investors understand that consolidating shares does not create value. The company's total market capitalization remains the same immediately after the split. The real test is whether Artelo can leverage this new lease on its public life to deliver on its business promises. The market’s skepticism is often justified; many post-split companies see their share prices erode again if the underlying business fundamentals do not improve.

A Lifeline for a High-Stakes Pipeline

Beyond the financial engineering, Artelo's survival hinges on its scientific mission: developing therapies by modulating lipid-signaling pathways to treat cancer, pain, and other conditions. The reverse split is ultimately a tool to buy time and secure the capital necessary to advance its promising, yet cash-intensive, clinical pipeline.

The company is developing several key drug candidates, including ART27.13 for cancer-related anorexia, ART26.12 for chemotherapy-induced peripheral neuropathy, and a patented CBD cocrystal, ART12.11, for inflammatory conditions. Progressing these assets through clinical trials requires tens of millions of dollars, and access to public capital markets is essential.

Artelo’s recent history is marked by a continuous search for funding. It conducted private placements in June and August of 2025, and in February 2026, it announced a new “staged equity purchase deal” for up to $50 million. The company’s financial strategies have at times been unconventional, such as a 2025 plan to use proceeds from a share sale to purchase the cryptocurrency Solana (SOL), a move that signaled a high-risk approach to treasury management. These constant capital-raising efforts underscore the precarious financial position of a clinical-stage biotech and explain why maintaining a Nasdaq listing is non-negotiable.

The Biotech Reverse Split: A Common but Cautionary Tale

Artelo is far from the first biotech company to resort to a reverse stock split. The move is a well-trodden path in a sector characterized by long development timelines, high cash burn, and binary clinical trial outcomes. For many, it is a necessary evil to maintain access to the capital needed for innovation.

Yet, the long-term track record for such companies is mixed at best. While the split can provide a temporary reprieve, it often serves as a red flag for investors, signaling that a company is struggling. The ultimate success or failure of the strategy depends entirely on what happens next.

The stakes are now higher due to recent changes in Nasdaq's own rules. Under stricter guidelines approved in 2025, if a company's stock price falls below the $1.00 minimum within a year following a reverse split, it may face expedited delisting without the grace of another compliance period. This puts immense pressure on Artelo's management to not only achieve a higher stock price but to sustain it with positive clinical data, strategic partnerships, or improved financial health. For Artelo Biosciences, the clock has been reset, but it is ticking louder than ever.